Veracyte Inc (FRA:12V)
€ 39.4 0.8 (2.07%) Market Cap: 3.16 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 2.76 GF Score: 81/100

Q4 2019 Veracyte Inc Earnings Call Transcript

Feb 25, 2020 / 10:00PM GMT
Release Date Price: €22 (-2.65%)
Operator

Good afternoon, ladies and gentlemen. And welcome to the Veracyte Fourth Quarter and Full Year 2019 Financial Results Conference Call. As a reminder, today's conference call is being recorded.

I'd now like to turn the conference over to Keith Kennedy, Veracyte's Chief Operating Officer and Chief Financial Officer. You may begin.

Keith S. Kennedy
Veracyte, Inc. - CFO, COO & Secretary

Good afternoon, everyone. And thanks for joining us today for a discussion of our fourth quarter and full year 2019 financial results.

With me today are Bonnie Anderson, Veracyte's Chairman and Chief Executive Officer; Dr. Giulia Kennedy, our Chief Scientific and Medical Officer; and John Hanna, our Chief Commercial Officer.

Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements include those regarding our future plans, prospects and strategy, financial goals and guidance, product attributes and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot